[Combination of PD-1 Inhibitor and Chemotherapy in the Treatment of Nasal NK/T Cell Lymphoma: 5 Cases Report and Literature Review]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2018 May 21

PMID 29779354

Citations 1

Authors

M Y Liu

Y F Li

J W Du

L H Dong

Y S Wang

X Gao

X D Wei

Y P Song

Affiliations

Soon will be listed here.

Citing Articles

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress.

Harabuchi Y, Takahara M, Kishibe K, Nagato T, Kumai T Front Pediatr. 2019; 7:141.

PMID: 31041299 PMC: 6476925. DOI: 10.3389/fped.2019.00141.

References

Li Y, Fang H, Liu Q, Lu J, Qi S, Wang H . Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood. 2008; 112(8):3057-64. DOI: 10.1182/blood-2008-05-160176. View

Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y . Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother. 2017; 66(7):877-890. PMC: 11028583. DOI: 10.1007/s00262-017-1987-x. View

Bi X, Wang H, Zhang W, Wang J, Liu W, Xia Z . PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol. 2016; 9(1):109. PMC: 5064887. DOI: 10.1186/s13045-016-0341-7. View

Yamaguchi M, Kwong Y, Kim W, Maeda Y, Hashimoto C, Suh C . Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011; 29(33):4410-6. DOI: 10.1200/JCO.2011.35.6287. View

Naidoo J, Page D, Li B, Connell L, Schindler K, Lacouture M . Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015; 26(12):2375-91. PMC: 6267867. DOI: 10.1093/annonc/mdv383. View

Tse E, Kwong Y . How I treat NK/T-cell lymphomas. Blood. 2013; 121(25):4997-5005. DOI: 10.1182/blood-2013-01-453233. View

Tse E, Kwong Y . Diagnosis and management of extranodal NK/T cell lymphoma nasal type. Expert Rev Hematol. 2016; 9(9):861-71. DOI: 10.1080/17474086.2016.1206465. View

Kwong Y, Chan T, Tan D, Kim S, Poon L, Mow B . PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017; 129(17):2437-2442. DOI: 10.1182/blood-2016-12-756841. View

Li Y, Liu Q, Fang H, Qi S, Wang H, Wang W . Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res. 2009; 15(8):2905-12. DOI: 10.1158/1078-0432.CCR-08-2914. View

10.

Li Y, Liu Q, Wang W, Jin J, Song Y, Wang S . Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy. Cancer. 2011; 117(22):5203-11. DOI: 10.1002/cncr.26167. View

11.

Liang R . Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type. Br J Haematol. 2009; 147(1):13-21. DOI: 10.1111/j.1365-2141.2009.07802.x. View

12.

Liu Y, Song Y, Zhu J . [Research progress on PD-1 inhibitors in lymphoma therapy]. Zhonghua Xue Ye Xue Za Zhi. 2016; 37(9):829-832. PMC: 7342112. DOI: 10.3760/cma.j.issn.0253-2727.2016.09.021. View

13.

Tse E, Chan T, Koh L, Chng W, Kim W, Tang T . Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group. Bone Marrow Transplant. 2014; 49(7):902-6. DOI: 10.1038/bmt.2014.65. View

14.

Li B, VanRoey M, Wang C, Chen T, Korman A, Jooss K . Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res. 2009; 15(5):1623-34. DOI: 10.1158/1078-0432.CCR-08-1825. View